Drag a card by its title · ⚙ to size, swap or remove

The company

bioAffinity Technologies, Inc.

BIAF · Nasdaq

Health CareLife-science toolsNot moving yet

BIAF stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 82.2% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 52
Industry in uptrend: 52% +4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 16 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months0

Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders16+2 on the quarter

New · exited6 · 4

Reported value$748K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
SABBY MANAGEMENT, LLCnew · filed 14 Aug 2026	365,647$297K	+365,647
BlackRock, Inc.new · filed 7 Aug 2026	98,777$80K	+98,777
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026	55,543$45K	00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	50,967$41K	+2,674+5.5%
J. Safra Sarasin Holding AGunchanged · filed 31 Jul 2026	42,600$164K	00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026	31,071$25K	00.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 2026	26,870$22K	+26,870
JANE STREET GROUP, LLCnew · filed 14 Aug 2026	26,784$22K	+26,784
STATE STREET CORPadded · filed 7 Aug 2026	24,086$20K	+9,700+67.4%
NORTHERN TRUST CORPadded · filed 13 Aug 2026	16,748$14K	+4,023+31.6%

31 Mar 2023 – 30 Jun 2026

News

Biotech Stock bioAffinity Technologies (Nasdaq: BIAF) Soars on Japanese Patent Allowanceinvestorideas.com · 8 Oct 2026

Everyone who traded it

James Michael Edwards VP and CFO · last 10 Jan 20251 · 0

Maria Zannes President & CEO · last 10 Jan 20251 · 0

Steven Girgenti Executive Chairman · last 10 Jan 20251 · 0

Timothy P. Zannes Secretary, EVP, Gen. Counsel · last 10 Jan 20250 · 0

Xavier Trinidad Reveles Chief Operating Officer · last 10 Jan 20250 · 0

Gary D. Rubin Director, 10% owner · last 1 Jul 20240 · 0

Jamie Platt Director · last 1 Jul 20240 · 0

Peter S. Knight Director · last 1 Jul 20241 · 0

Robert A. Anderson Director · last 1 Jul 20241 · 0

Roby Joyce Director · last 1 Jul 20240 · 0

Stuart Diamond Director · last 1 Jul 20241 · 0

Harvey Sandler Revocable Trust 10% owner · last 12 Jun 20241 · 0

Same industry

OABI OmniAbLeading+65%

TXG 10x GenomicsLeading+60%

AVTR AvantorLeading+47%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+37%

CRL Charles River Laboratories InternationalLeading+35%

MASS 908 DevicesLeading+31%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-172%

Free cash flow marginFY 2025 · to 31 Dec 2025-152%

Return on capital employedFY 2025 · to 31 Dec 2025-131%

Research spendFY 2025 · to 31 Dec 202522.4%

Share count trendFY 2025 · to 13 Mar 20260.0%

Cash and equivalentsFY 2025 · to 31 Dec 2025$6.4M

Free cash flowFY 2025 · to 31 Dec 2025−$9.4M

Analyst forecasts

No analyst forecasts yet.